Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two Patents, Seven Patent Applications Related to RNAi

Premium
USPTO Publishes Two Patents, Seven Patent Applications Related to RNAi
 
 
Title: Oligoribonucleotides and Ribonucleases for Cleaving RNA
 
Number: 7,432,250, 7,432,249
 
Filed: Oct. 25, 2002
 
Inventor: Stanley Crooke, Isis Pharmaceuticals
 
The patents, their abstracts state, claim “oligomeric compounds including oligoribonucleotides and oligoribonucleosides … that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.”
 
The patents also claim “mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases,” according to the abstracts. “Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.”
 

 
Title: Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases
 
Number: 20080241198
 
Filed: June 29, 2007
 
Lead Inventor: Yijia Liu, Intradigm
 
The patent application, its abstract states, claims “compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological [neovascularization] tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference … [and] can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists” are covered by the patent application, the abstract adds. “The compositions and methods can be used for the treatment of [neovascularization] diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.”
 

 
Title: Vector Constructs
 
Number: 20080241894
 
Filed: March 26, 2008
 
Lead Inventor: Geert Plaetinck, Devgen
 
The patent application, its abstract states, claims “improved vector constructs useful in the expression of double-stranded RNA. … The constructs are particularly useful for expression of double-stranded RNA in vitro and in vivo.”
 

 
Title: Nucleotide-Cochleate Compositions and Methods of Use
 
Number: 20080242625
 
Filed: April 11, 2005 PCT Filed: April 11, 2005
 
Lead Inventor: Raphael Mannino, BioDelivery Sciences International
 
The invention “is directed to cochleate composition that [includes] a nucleotide,” the patent application’s abstract states. “The nucleotide may generally be bound via a linker to a component of the cochleate, or to a lipophilic tail. Additionally or alternatively, the nucleotide may be associated with a transfection agent. The … invention also includes methods for making and using the compositions provided herein.”
 

 
Title: Novel RNA Interference Methods Using DNA-RNA Duplex Constructs
 
Number: 20080242627
 
Filed: Oct. 11, 2007
 
Lead Inventor: Shao-Yao Ying, University of Southern California
 
The invention, according to the patent application’s abstract, “provides novel compositions and methods for suppressing the function or activity of a targeted gene through a novel intracellular piRNA-mediated RNAi mechanism, using RNA-DNA duplex constructs. The invention further provides novel methods and compositions for generating or producing RNA-DNA duplex agents, whose quantity is high enough to be used for the invention's gene silencing transfection and possibly in therapeutics applications. This improved RNA-polymerase chain reaction method utilizes thermocycling steps of promoter-linked DNA or RNA template synthesis, in vitro transcription and then reverse transcription to bring up the amount of RNA-DNA duplexes up to two thousand folds within one round of the above procedure for using in D-RNAi-directed gene silencing.”
 

 
Title: Inhibiting Gene Expression with dsRNA
 
Number: 20080242628
 
Filed: Oct. 31, 2007
 
Lead Inventor: Magdalena Zernicka-Goetz, Cancer Research Technology (Alnylam Pharmaceuticals)
 
The invention, the patent application’s abstract states, “relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double-stranded RNA.”
 

 
Title: Multi-Targeting Short Interfering RNAs
 
Number: 20080242632
 
Filed: Jan. 29, 2008
 
Lead Inventor: John Rossi, City of Hope
 
The invention “relates to novel short interfering RNA molecules that are multi-targeted,” the patent application’s abstract states. “More specifically, the … invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of microRNA molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets.” 
 

 
Title: Modified Polynucleotides for Reducing Off-Target Effects in RNA Interference
 
Number: 20080242851
 
Filed: Sept. 19, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
The patent application, its abstract states, claims “methods and compositions for performing RNA interference with decreased off-target effects. … The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2'-O-alkyl or mismatch modification(s) at specific positions on the sense and/or antisense strands.”
 
 
 

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.